Anti‐CD20 therapeutic options in immune‐mediated thrombotic thrombocytopenic purpura

Immunosuppression with rituximab in immune‐mediated thrombotic thrombocytopenic purpura helps decrease production of autoantibody mediating ADAMTS13 clearance from circulation. Failure to respond to rituximab in a satisfactory way or made difficult by adverse events to the medication does not repres...

Descripción completa

Detalles Bibliográficos
Autor principal: Maitta, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540546/
https://www.ncbi.nlm.nih.gov/pubmed/35472189
http://dx.doi.org/10.1111/bjh.18215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540546/
https://www.ncbi.nlm.nih.gov/pubmed/35472189
http://dx.doi.org/10.1111/bjh.18215

Ejemplares similares